Display options
Cite
Balfour HH, Dunmire SK, Hogquist KA. Infectious mononucleosis. Clin Transl Immunology. 2015;4(2):e33doi: 10.1038/cti.2015.1.
Balfour, H. H., Dunmire, S. K., & Hogquist, K. A. (2015). Infectious mononucleosis. Clinical & translational immunology, 4(2), e33. https://doi.org/10.1038/cti.2015.1
Balfour, Henry H, et al. "Infectious mononucleosis." Clinical & translational immunology vol. 4,2 (2015): e33. doi: https://doi.org/10.1038/cti.2015.1
Balfour HH, Dunmire SK, Hogquist KA. Infectious mononucleosis. Clin Transl Immunology. 2015 Feb 27;4(2):e33. doi: 10.1038/cti.2015.1. eCollection 2015 Feb. PMID: 25774295; PMCID: PMC4346501.
Copy Download .nbib Format: NLM
Share it on

Clin Transl Immunology. 2015 Feb 27;4(2):e33. doi: 10.1038/cti.2015.1. eCollection 2015 Feb.

Infectious mononucleosis.

Clinical & translational immunology

Henry H Balfour, Samantha K Dunmire, Kristin A Hogquist

Affiliations

  1. Department of Laboratory Medicine and Pathology, University of Minnesota Medical School , Minneapolis, MN, USA ; Department of Pediatrics, University of Minnesota Medical School , Minneapolis, MN, USA.
  2. Department of Laboratory Medicine and Pathology, University of Minnesota Medical School , Minneapolis, MN, USA.

PMID: 25774295 PMCID: PMC4346501 DOI: 10.1038/cti.2015.1

Abstract

Infectious mononucleosis is a clinical entity characterized by pharyngitis, cervical lymph node enlargement, fatigue and fever, which results most often from a primary Epstein-Barr virus (EBV) infection. EBV, a lymphocrytovirus and a member of the γ-herpesvirus family, infects at least 90% of the population worldwide, the majority of whom have no recognizable illness. The virus is spread by intimate oral contact among adolescents, but how preadolescents acquire the virus is not known. During the incubation period of approximately 6 weeks, viral replication first occurs in the oropharynx followed by viremia as early as 2 weeks before onset of illness. The acute illness is marked by high viral loads in both the oral cavity and blood accompanied by the production of immunoglobulin M antibodies against EBV viral capsid antigen and an extraordinary expansion of CD8(+) T lymphocytes directed against EBV-infected B cells. During convalescence, CD8(+) T cells return to normal levels and antibodies develop against EBV nuclear antigen-1. A typical clinical picture in an adolescent or young adult with a positive heterophile test is usually sufficient to make the diagnosis of infectious mononucleosis, but heterophile antibodies are not specific and do not develop in some patients especially young children. EBV-specific antibody profiles are the best choice for staging EBV infection. In addition to causing acute illness, long-term consequences are linked to infectious mononucleosis, especially Hodgkin lymphoma and multiple sclerosis. There is no licensed vaccine for prevention and no specific approved treatment. Future research goals are development of an EBV vaccine, understanding the risk factors for severity of the acute illness and likelihood of developing cancer or autoimmune diseases, and discovering anti-EBV drugs to treat infectious mononucleosis and other EBV-spurred diseases.

References

  1. Nat Med. 1996 Aug;2(8):906-11 - PubMed
  2. J Immunol. 2014 May 15;192(10):4492-6 - PubMed
  3. J Immunol. 2013 Nov 15;191(10):4989-95 - PubMed
  4. Proc Natl Acad Sci U S A. 2011 Sep 6;108(36):14725-32 - PubMed
  5. J Clin Pathol. 1976 Sep;29(9):841-7 - PubMed
  6. J Virol. 2008 Feb;82(3):1448-57 - PubMed
  7. J Exp Med. 1998 Mar 2;187(5):813-8 - PubMed
  8. J Clin Virol. 1998 Dec;11(3):161-72 - PubMed
  9. Blood. 1981 May;57(5):933-8 - PubMed
  10. Br J Haematol. 2005 Apr;129(2):266-74 - PubMed
  11. J Immunol. 2000 Dec 15;165(12):7078-87 - PubMed
  12. N Engl J Med. 2003 Oct 2;349(14):1324-32 - PubMed
  13. Immunol Rev. 2005 Feb;203:165-79 - PubMed
  14. J Exp Med. 1965 May 1;121:761-70 - PubMed
  15. Clin Transl Immunology. 2015 Jan 23;4(1):e32 - PubMed
  16. Annu Rev Immunol. 2007;25:587-617 - PubMed
  17. J Infect Dis. 2013 Jan 1;207(1):80-8 - PubMed
  18. Clin Immunol Immunopathol. 1984 Mar;30(3):437-50 - PubMed
  19. Blood. 2010 Nov 18;116(20):4158-67 - PubMed
  20. Antivir Chem Chemother. 2013 Jan 23;23(3):93-101 - PubMed
  21. Proc Natl Acad Sci U S A. 1987 Jan;84(2):570-4 - PubMed
  22. N Engl J Med. 2010 May 27;362(21):1993-2000 - PubMed
  23. J Exp Med. 2012 Mar 12;209(3):471-8 - PubMed
  24. Wis Med J. 1985 Dec;84(12):19-25 - PubMed
  25. Epidemiol Infect. 2012 Nov;140(11):2089-95 - PubMed
  26. Am J Med Sci. 1955 Mar;229(3):262-72 - PubMed
  27. Clin Microbiol Rev. 2011 Jan;24(1):193-209 - PubMed
  28. Ann Intern Med. 1957 Jun;46(6):1184-91 - PubMed
  29. Clin J Sport Med. 2008 Jul;18(4):309-15 - PubMed
  30. Viral Immunol. 2009 Feb;22(1):67-72 - PubMed
  31. J Clin Microbiol. 1999 Oct;37(10):3239-44 - PubMed
  32. PLoS One. 2014 Jan 17;9(1):e85422 - PubMed
  33. J Virol. 1998 Jul;72(7):5552-8 - PubMed
  34. Lancet. 1969 Mar 22;1(7595):593-5 - PubMed
  35. Proc Natl Acad Sci U S A. 2004 Nov 23;101(47):16606-11 - PubMed
  36. Blood. 2014 Oct 16;124(16):2533-43 - PubMed
  37. J Immunol. 2013 Dec 1;191(11):5398-409 - PubMed
  38. Proc Natl Acad Sci U S A. 1968 Jan;59(1):94-101 - PubMed
  39. J Virol. 2007 Jan;81(2):474-82 - PubMed
  40. J Clin Invest. 2005 Dec;115(12):3602-12 - PubMed
  41. Immunol Cell Biol. 2011 Mar;89(3):408-16 - PubMed
  42. Sci Transl Med. 2011 Nov 2;3(107):107fs7 - PubMed
  43. Cancer Res. 1981 Nov;41(11 Pt 1):4253-61 - PubMed
  44. Blood. 1988 May;71(5):1234-43 - PubMed
  45. Br J Haematol. 2013 Sep;162(5):573-86 - PubMed
  46. Am J Clin Pathol. 1979 Nov;72(5):807-11 - PubMed
  47. Nature. 2007 May 17;447(7142):326-9 - PubMed
  48. Nat Med. 2002 Jun;8(6):594-9 - PubMed
  49. Curr Opin Pediatr. 2000 Jun;12(3):263-8 - PubMed
  50. Nature. 2006 Nov 2;444(7115):110-4 - PubMed
  51. J Exp Med. 2013 May 6;210(5):933-49 - PubMed
  52. Dev Biol Stand. 1995;84:171-7 - PubMed
  53. J Immunol. 2013 Feb 15;190(4):1672-84 - PubMed
  54. Clin Infect Dis. 2014 Jun;58(12):1684-9 - PubMed
  55. J Infect Dis. 2007 Dec 15;196(12):1724-6 - PubMed
  56. J Infect Dis. 2005 Nov 1;192(9):1505-12 - PubMed
  57. J Clin Microbiol. 2004 Sep;42(9):4411 - PubMed
  58. Annu Rev Microbiol. 1973;27:413-36 - PubMed
  59. Blood. 1996 Jan 15;87(2):812-7 - PubMed
  60. Lancet. 1964 Mar 28;1(7335):702-3 - PubMed
  61. Am J Epidemiol. 1977 May;105(5):480-7 - PubMed
  62. J Clin Virol. 2007 Apr;38(4):292-7 - PubMed
  63. Pediatr Neurol. 1994 May;10(3):181-4 - PubMed
  64. PLoS One. 2010 Sep 01;5(9):null - PubMed
  65. PLoS Biol. 2011 Nov;9(11):e1001187 - PubMed
  66. J Exp Med. 1998 May 4;187(9):1395-402 - PubMed
  67. PLoS Pathog. 2008 Feb 8;4(2):e27 - PubMed
  68. Cell Rep. 2013 Dec 26;5(6):1489-98 - PubMed
  69. J Clin Microbiol. 2004 Aug;42(8):3381-7 - PubMed
  70. J Clin Virol. 2007 May;39(1):16-21 - PubMed
  71. J Infect Dis. 1986 Nov;154(5):842-50 - PubMed
  72. J Infect Dis. 2007 Dec 15;196(12):1749-53 - PubMed
  73. Clin Infect Dis. 2006 Aug 1;43(3):276-82 - PubMed
  74. Clin Vaccine Immunol. 2014 Jun;21(6):817-23 - PubMed

Publication Types

Grant support